Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.
3.

Screening for prostate cancer: an update.

Bryant RJ, Hamdy FC.

Eur Urol. 2008 Jan;53(1):37-44. Epub 2007 Aug 27. Review.

PMID:
17826892
4.
5.

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force.

Harris R, Lohr KN.

Ann Intern Med. 2002 Dec 3;137(11):917-29. Review.

PMID:
12458993
6.

Screening for prostate cancer: a Cochrane systematic review.

Ilic D, O'Connor D, Green S, Wilt T.

Cancer Causes Control. 2007 Apr;18(3):279-85. Epub 2007 Jan 6. Review.

PMID:
17206534
7.

Update on screening and early detection of prostate cancer.

Otto SJ, de Koning HJ.

Curr Opin Urol. 2004 May;14(3):151-6. Review.

PMID:
15069305
8.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
9.

Should prostate-specific antigen screening be offered to asymptomatic men?

van Vugt HA, Bangma CH, Roobol MJ.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64. Review.

PMID:
20645694
10.

Screening for prostate cancer.

Schröder FH.

Urol Clin North Am. 2003 May;30(2):239-51, viii. Review.

PMID:
12735501
11.

Prostate cancer: to screen or not to screen.

Bailey SJ, Brewster SF.

Arch Esp Urol. 2011 Jun;64(5):406-18. Review. English, Spanish.

PMID:
21705812
12.
13.

Randomized trial results did not resolve controversies surrounding prostate cancer screening.

Hoffman RM.

Curr Opin Urol. 2010 May;20(3):189-93. doi: 10.1097/MOU.0b013e3283383b55. Review.

PMID:
20224414
14.

Screening, early detection, and treatment of prostate cancer: a European view.

Schröder FH.

Urology. 1995 Sep;46(3 Suppl A):62-70. Review.

PMID:
7653022
15.

Early diagnosis of prostate cancer.

Gerber GS, Chodak GW.

Important Adv Oncol. 1993:93-101. Review.

PMID:
7685000
16.

Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial.

Miller AB, Madalinska JB, Church T, Crawford D, Essink-Bot ML, Goel V, de Koning HJ, Määttänen L, Pentikäinen T.

Eur J Cancer. 2001 Nov;37(17):2154-60. Review.

PMID:
11677101
17.

Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.

McNaughton-Collins M, Walker-Corkery E, Barry MJ.

J Natl Cancer Inst Monogr. 2004;(33):78-101. Review.

PMID:
15504921
18.

Unanswered questions in screening for prostate cancer.

Neal DE, Leung HY, Powell PH, Hamdy FC, Donovan JL.

Eur J Cancer. 2000 Jun;36(10):1316-21. Review.

PMID:
10882874
19.

A review of prostate-specific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer.

McDowell ME, Occhipinti S, Gardiner RA, Baade PD, Steginga SK.

Eur J Cancer Care (Engl). 2009 Nov;18(6):545-55. doi: 10.1111/j.1365-2354.2008.01046.x. Review.

PMID:
19686273
20.

Screening for prostate cancer.

Postma R, Schröder FH.

Eur J Cancer. 2005 Apr;41(6):825-33. Review.

PMID:
15808952

Supplemental Content

Support Center